New markers (CD160, CD200, and LAIR-1) in diagnosis of B-cell lymphoproliferative disorders

Flow cytometry is used in diagnosis and classification of B-cell lymphoproliferative disorders, measuring expression level of target antigen and monitoring of minimal residual disease. Immunological phenotype of tumor B cells is not always in accord with classical characteristic and it makes complicated the interpretation of data, and therefore there is a need to find additional informative markers. Using new monoclonal antibodies to CD160, CD200 and LAIR-1 enhances the diagnostic capabilities of flow cytometry.

• S.A. Lugovskaya Russian Medical Academy for Postgraduate Education of Ministry of Health, Moscow, Russian Federation ; ГБОУ ДПО Российская медицинская академия последипломного образования МЗ РФ, Москва, Российская Федерация
• D.G. Kisilichina Russian Medical Academy for Postgraduate Education of Ministry of Health, Moscow, Russian Federation ; ГБОУ ДПО Российская медицинская академия последипломного образования МЗ РФ, Москва, Российская Федерация
• M.E. Pochtar Russian Medical Academy for Postgraduate Education of Ministry of Health, Moscow, Russian Federation ; ГБОУ ДПО Российская медицинская академия последипломного образования МЗ РФ, Москва, Российская Федерация
• E.V. Naumova Russian Medical Academy for Postgraduate Education of Ministry of Health, Moscow, Russian Federation ; ГБОУ ДПО Российская медицинская академия последипломного образования МЗ РФ, Москва, Российская Федерация
• E.A. Nikitin FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический Научный Центр» МЗ РФ, Москва, Российская Федерация
• L.S. Al-Rad FSBI «Haematological Research Center» Russian Ministry of Health, Moscow, Russian Federation ; ФГБУ «Гематологический Научный Центр» МЗ РФ, Москва, Российская Федерация

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press, 2008.
2. Liu F.-T., Qiustiniani J., Farren T. et al. CD160 signaling mediates PI3Kdependent survival and growth signals in chronic lymphocytic leukemia. Blood 2010; 115: 3079–88. DOI: https://doi.org/10.1182/blood-2009-08-239483
3. Le Bouteiller P., Tabiasco J., Polgar B. et al. CD160: a unique activating NK cell receptor. Immunol. Lett. 2011; 138: 93–6. DOI: https://doi.org/10.1016/j.imlet.2011.02.003
4. Farren T., Liu F.-T., Stephens C. et al. Inter-Laboratory Assessment of Minimal Residual Disease In Chronic Lymphocytic Leukemia — Evaluation of the Novel CD160FCA Assay. Blood, ASH #2723. DOI: https://doi.org/10.1182/blood.V116.21.2723.2723
5. Farren T., Qiustiniani J., Liu F.-T. et al. Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood 2011; 118: 2174–83. DOI: https://doi.org/10.1182/blood-2011-02-334326
6. Brunetti L., Di’Giovanna Abate R. et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br. J. Haematol. 2009; 145: 665–7. DOI: https://doi.org/10.1111/j.1365-2141.2009.07644.x
7. Gambell P., Cargo C., Nguyen V. et al. CD200 Expression Using Flow Cytometry In B-Cell Lymphoproliferative Disorders. Int. J. Lab. Hem 2011; 33(Suppl. 1): 51–2.
8. Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin. Diagn. Pathol. 2011; 28: 245–55. DOI: https://doi.org/10.1053/j.semdp.2011.02.010
9. Moreaux J., Hose D., Reme T., Jourdan E. CD200 is a new prognostic factor in multiple myeloma. Blood 2006; 108: 4194–7. DOI: https://doi.org/10.1182/blood-2006-06-029355
10. Olteanu H., Harrington A.M., Parameswaran H., Kroft S.H. CD200 expression in plasma cell myeloma. Br. J. Haematol. 2011; 153: 402–16. DOI: https://doi.org/10.1111/j.1365-2141.2010.08555.x
11. El Desoukey N.A., Afify R.A., Amin D.G., Mohammed R.F. CD200 expression in B-cell chronic lymphoproliferative disorders. J. Investig. Med. 2012; 60: 56–61. DOI: https://doi.org/10.2310/JIM.0b013e31823908f9
12. Harma T., Brondijk C., de Ruiter T. et al. Crystal structure and collagenbinding site of immune inhibitory receptor LAIR-1: unexpected implications for collagen binding by platelet receptor GPVI. Blood 2010; 115: 1364–73. DOI: https://doi.org/10.1182/blood-2009-10-246322
13. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J. Leuk. Biol. 2008; 83: 799–803. DOI: https://doi.org/10.1189/jlb.0907609
14. van der Vuurst de Vries A.-R., Clevers H., Logtenberg T., Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptormediated signaling. Eur. J. Immunol. 1999; 29: 3160–7. DOI: https://doi.org/10.1002/(SICI)1521-4141(199910)29:10<3160::AID-IMMU3160>3.3.CO;2-J
15. Kretz-Rommel A., Bowdish K.S. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Exp. Opin. Biol. Ther. 2008; 8: 5–15. DOI: https://doi.org/10.1517/14712598.8.1.5
16. Pallasch C.P., Ulbrich S., Brinker R. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk. Res. 2009; 33: 460–4. DOI: https://doi.org/10.1016/j.leukres.2008.08.021